The FDA approved caplacizumab (Cablivi by Sanofi) on 2/6/2019 for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
The FDA's Oncologic Drugs Advisory Committee will review Karyopharm Therapeutics’ selinexor on 2/26/2019. The FDA has granted Daiichi Sankyo/Plexxikon’s pexidartinib breakthrough therapy and orphan drug designations and set a PDUFA date of 8/3/2019.
Comments are closed.
|
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker Latest Tweets from Prescribe Right
Archives
May 2023
|
Services |
Company |
|
© COPYRIGHT 2015. ALL RIGHTS RESERVED.
|